Welcome to our dedicated page for Monopar Therapeutics news (Ticker: MNPR), a resource for investors and traders seeking the latest updates and insights on Monopar Therapeutics stock.
Monopar Therapeutics Inc. develops clinical and preclinical biopharmaceutical programs for Wilson disease and oncology radiopharmaceuticals. News about MNPR centers on ALXN1840, also described as tiomolibdate choline, a late-stage investigational oral therapy for Wilson disease, including analyses from the Phase 3 FoCus trial, copper-balance data, neurology and hepatology conference presentations, and related peer-reviewed publications.
Company updates also cover the MNPR-101 radiopharmaceutical programs for uPAR-expressing cancers, including MNPR-101-Zr imaging activity, MNPR-101-Lu therapeutic development and IND clearance, and preclinical MNPR-101-Ac work. Recurring corporate themes include financial results, public offerings, balance-sheet updates, and commercial or executive infrastructure as the company advances its pipeline.
Monopar Therapeutics (MNPR) has received authorization to proceed with the Phase 2b/3 VOICE clinical trial in France, targeting severe oral mucositis in oropharyngeal cancer patients undergoing chemoradiotherapy. This follows the trial's initiation in the US and is positioned to expand into other European countries shortly. The upcoming ESMO Congress will feature a presentation detailing the trial's design and rationale. The company anticipates reaching the interim results by early 2022. Validive, the treatment under evaluation, has shown promising Phase 2 results, reducing mucositis incidence significantly.
Monopar Therapeutics Inc. (Nasdaq: MNPR) announced that its CEO, Chandler D. Robinson, will present an overview of the company at two upcoming investor conferences in September 2021. The first presentation will be at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 7:00 a.m. ET. The second will occur at the Cantor Virtual Global Healthcare Conference 2021 on September 30, 2021, at 11:20 a.m. ET. Monopar focuses on developing therapeutics aimed at extending life and improving the quality of life for cancer patients.
Monopar Therapeutics (MNPR) announced its Q2 2021 financial results and key business advancements. The Phase 2b/3 VOICE trial of Validive has activated 20 sites and is expected to reach interim analysis in H1 2022. The FDA cleared the Phase 1b trial for camsirubicin in soft tissue sarcoma, with patient dosing anticipated in Q4 2021. The company also established a collaboration with the Cancer Science Institute of Singapore for MNPR-202 research. As of June 30, 2021, cash stood at $24.3 million, supporting operations through September 2022.
Monopar Therapeutics (Nasdaq: MNPR) announced the activation of 20 clinical trial sites for the Phase 2b portion of the Validive VOICE trial, aimed at preventing severe oral mucositis in oropharyngeal cancer patients. This milestone reflects higher-than-expected site enrollment rates. The company plans to expand the trial to additional sites and countries due to strong interest. An interim analysis of the trial is anticipated in the first half of 2022. Validive is a self-administered tablet addressing a significant patient need, impacting the lives of over 40,000 U.S. patients annually.
Monopar Therapeutics (Nasdaq: MNPR) announced FDA clearance to proceed with a Phase 1b trial for camsirubicin in patients with advanced soft tissue sarcoma. This open-label dose-escalation trial aims to explore the potential of camsirubicin, combined with growth factor support (pegfilgrastim), to extend dosing duration compared to doxorubicin. The Company expects to dose the first patient in Q4 2021. If successful, camsirubicin could be evaluated for 13 other cancer indications.
Monopar Therapeutics Inc. (Nasdaq: MNPR) appointed Dr. Octávio Costa as Chief Medical Officer, effective immediately. Dr. Costa brings over 30 years of experience in clinical development and regulatory affairs, previously serving in significant roles at Merck, Celgene, and Novartis. His expertise in navigating all clinical phases will be crucial as Monopar advances its pipeline, which includes innovative cancer therapies. CEO Chandler Robinson expressed confidence in Dr. Costa’s ability to accelerate the company’s clinical efforts as they enter late-stage studies.
Monopar Therapeutics Inc. (Nasdaq: MNPR) announced the presentation of its oropharyngeal cancer (OPC) patient population analysis from the Phase 2 Validive trial at the MASCC/ISOO 2021 annual meeting. This analysis supports the design of the Phase 2b/3 VOICE trial, which is currently recruiting OPC patients in the US. Validive is aimed at preventing severe oral mucositis caused by chemoradiotherapy, with prior Phase 2 results showing a relative incidence reduction of 40% compared to placebo. The presentation will be available on demand beginning June 25, 2021.
Monopar Therapeutics Inc. (Nasdaq: MNPR) announced a collaboration with the Cancer Science Institute of Singapore to evaluate its new drug MNPR-202, designed to treat chemotherapy-resistant cancers. MNPR-202 maintains a potentially non-cardiotoxic structure similar to camsirubicin but is modified to target cancers that resist traditional therapies. This partnership aims to deepen the understanding of MNPR-202’s impact on cancer cells and its potential to enhance immunotherapy treatments. A clinical trial for camsirubicin is set to begin in late 2021.
Monopar Therapeutics Inc. (Nasdaq: MNPR) announced the appointment of Andrew Cittadine as Chief Operating Officer on June 1, 2021. Cittadine brings extensive experience in healthcare, having founded successful companies such as Sensant Corp. and American Biooptics. He will oversee Monopar's global operations and business strategy, contributing to their goal of developing therapeutics for cancer patients. Monopar's pipeline includes Validive, camsirubicin, and the preclinical antibody MNPR-101. CEO Chandler Robinson expressed confidence in Cittadine’s leadership during this pivotal time for the company.
Monopar Therapeutics (MNPR) and NorthStar Medical Radioisotopes have filed a provisional patent for a radiotherapeutic combining Monopar's MNPR-101 antibody with Actinium-225. The Radio-Immuno-Therapeutic (RIT) shows 98% radiochemical purity, indicating potential as an effective treatment for certain cancers and severe COVID-19.
This development may also allow for more efficient production with reduced material use, thus improving supply chain logistics. If granted, the patent could significantly enhance MNPR-101’s patent estate.